Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 31.55

-0.3%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	2/23/2015 1:57:00 PM
	of 566

Rigel Pharmaceuticals (RIGL) Bounce Warranted, Says Wells Fargo 10:19 AM ET, 02/23/2015 - StreetInsider Wells Fargo maintained a Market Perform rating on Rigel Pharmaceuticals (NASDAQ: RIGL). Earlier the company said it and Bristol-Myers Squibb Company announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. Bristol-Myers Squibb will pay $30 million upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309 million for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration. Commenting on developments, analyst Brian Abrahams said he remains cautious on prospects of its lead ITP program, but he went on to call the stock's bounce today warranted given reasonable terms on TGF-beta.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next